DOP2017000244A - Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) - Google Patents
Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)Info
- Publication number
- DOP2017000244A DOP2017000244A DO2017000244A DO2017000244A DOP2017000244A DO P2017000244 A DOP2017000244 A DO P2017000244A DO 2017000244 A DO2017000244 A DO 2017000244A DO 2017000244 A DO2017000244 A DO 2017000244A DO P2017000244 A DOP2017000244 A DO P2017000244A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- flap
- inhibitors
- useful
- activating protein
- lipoxygenase activating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a compuestos de fórmula (I) a su utilidad para tratar y/o prevenir afecciones clínicas incluyendo enfermedades cardiovasculares (ECV), a métodos para su uso terapéutico, a composiciones farmacéuticas que los contienen y a procesos para preparar dichos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562156424P | 2015-05-04 | 2015-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2017000244A true DOP2017000244A (es) | 2017-11-15 |
Family
ID=55910253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2017000244A DOP2017000244A (es) | 2015-05-04 | 2017-10-20 | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) |
Country Status (38)
Country | Link |
---|---|
US (6) | US10183947B2 (es) |
EP (2) | EP3670499B1 (es) |
JP (1) | JP6564062B2 (es) |
KR (1) | KR102623474B1 (es) |
CN (1) | CN107646036B (es) |
AR (1) | AR104512A1 (es) |
AU (1) | AU2016258874B2 (es) |
BR (1) | BR112017022757B1 (es) |
CA (1) | CA2983668C (es) |
CL (1) | CL2017002660A1 (es) |
CO (1) | CO2017011506A2 (es) |
CR (1) | CR20170513A (es) |
CY (2) | CY1122689T1 (es) |
DK (2) | DK3670499T3 (es) |
DO (1) | DOP2017000244A (es) |
EA (1) | EA032221B1 (es) |
ES (2) | ES2902139T3 (es) |
GT (1) | GT201700220A (es) |
HK (1) | HK1245255A1 (es) |
HR (2) | HRP20211993T1 (es) |
HU (2) | HUE047445T2 (es) |
IL (1) | IL255069B (es) |
LT (1) | LT3670499T (es) |
ME (1) | ME03663B (es) |
MX (1) | MX2017013571A (es) |
MY (1) | MY186647A (es) |
PE (1) | PE20180247A1 (es) |
PH (1) | PH12017502112B1 (es) |
PL (2) | PL3292105T3 (es) |
PT (2) | PT3670499T (es) |
RS (2) | RS62729B1 (es) |
SG (1) | SG11201708558RA (es) |
SI (2) | SI3670499T1 (es) |
SV (1) | SV2017005549A (es) |
TN (1) | TN2017000458A1 (es) |
TW (1) | TWI718146B (es) |
WO (1) | WO2016177703A1 (es) |
ZA (1) | ZA201708189B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2902139T3 (es) | 2015-05-04 | 2022-03-25 | Astrazeneca Ab | Derivados de pirazol útiles como inhibidores de la proteína activadora de 5-lipoxigenasa (FLAP) |
ES2933178T3 (es) * | 2016-10-28 | 2023-02-02 | Astrazeneca Ab | Forma cristalina de (1r,2r)-2-[4-(3-metil-1h-pirazol-5-il)benzoil]-n-(4-oxo-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-3-il)ciclohexanocarboxamida |
CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | 南京医科大学 | Mk571在制备预防和治疗心脏病药物中应用 |
CN111084775A (zh) * | 2020-02-17 | 2020-05-01 | 牡丹江医学院 | 一种用于治疗癫痫的药物组合物 |
CN111419800B (zh) * | 2020-04-23 | 2021-03-19 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗红斑狼疮的药物制剂及其制备方法 |
CN111643498B (zh) * | 2020-07-20 | 2021-05-07 | 黑龙江中医药大学 | 一种治疗肾结石的药物组合物及其用途 |
CN111714499B (zh) * | 2020-07-27 | 2021-05-11 | 黑龙江中医药大学 | 一种用于治疗多囊卵巢综合征的药物组合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109254A (en) | 1993-04-29 | 1999-03-12 | Zeneca Ltd | History of the tetrahydropyran and tetrahydropuran site preparation and pharmaceutical preparations containing them |
US5773422A (en) | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
CA2572750A1 (en) * | 2003-09-10 | 2005-03-17 | Anil Koul | Heterobicyclic compounds as pharmaceutically active agents |
GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
WO2008097930A1 (en) * | 2007-02-05 | 2008-08-14 | Amira Pharmaceuticals, Inc. | Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors |
GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
CN101686980A (zh) * | 2007-04-20 | 2010-03-31 | 先灵公司 | 四氢吡啶并[4,3-d]嘧啶酮衍生物及其使用方法 |
US9096546B2 (en) * | 2007-05-10 | 2015-08-04 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
JP2010540641A (ja) * | 2007-10-05 | 2010-12-24 | アミラ ファーマシューティカルス,インコーポレーテッド | 5−リポキシゲナーゼ活性化タンパク質(flap)阻害剤 |
ES2902139T3 (es) * | 2015-05-04 | 2022-03-25 | Astrazeneca Ab | Derivados de pirazol útiles como inhibidores de la proteína activadora de 5-lipoxigenasa (FLAP) |
-
2016
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en active Application Filing
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active IP Right Grant
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 MX MX2017013571A patent/MX2017013571A/es active IP Right Grant
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
-
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112B1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
-
2018
- 2018-04-06 HK HK18104539.0A patent/HK1245255A1/zh unknown
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
-
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-02 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
-
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
-
2023
- 2023-02-27 US US18/174,832 patent/US12024523B2/en active Active
-
2024
- 2024-05-21 US US18/670,264 patent/US20240317767A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
DOP2017000244A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap) | |
CO2017011851A2 (es) | Compuestos novedosos | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
BR112016018555A8 (pt) | Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1 | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
NI201800058A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer. | |
BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
BR112014009006B8 (pt) | Compostos heterocíclicos e métodos de uso dos mesmos | |
BR112016001645A8 (pt) | derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit | |
BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
CR20150432A (es) | Estra-1,3,5 (10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
BR112017006264A2 (pt) | derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório | |
DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
ECSP18056196A (es) | Derivados de indano | |
BR112017021114A8 (pt) | Compostos heterocíclicos como inibidores de lsd1 | |
BR112017009853A2 (pt) | composto, composição, uso de uma quantidade melhoradora de hiv de um composto |